le Coutre, Philipp

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Boquimpani, C., Pasquini, R., Clark, R. E., et al. (2021) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 351

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

Hochhaus, A., Wang, J., Kim, D.-W., Kim, D. D. H., Mayer, J., Goh, Y.-T., le Coutre, P., Takahashi, N., Kim, I., Etienne, G., et al. (2024) · New England Journal of Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 171

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Hochhaus, A., Réa, D., Boquimpani, C., Minami, Y., Cortes, J. E., Hughes, T. P., Apperley, J. F., Lomaia, E., Voloshin, S., Turkina, A., et al. (2023) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 148

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Hehlmann, R., Voskanyan, A., Lauseker, M., Pfirrmann, M., Kalmanti, L., Rinaldetti, S., Kohlbrenner, K., Haferlach, C., Schlegelberger, B., Fabarius, A., et al. (2020) · Leukemia

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 91

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia

Schönfeld, L., Rinke, J., Hinze, A., Nagel, S. N., Schäfer, V., Schenk, T., Fabisch, C., Brümmendorf, T. H., Burchert, A., le Coutre, P., et al. (2022) · Leukemia

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 57

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

Cortes, J. E., Sasaki, K., Kim, D.-W., Hughes, T. P., Etienne, G., Mauro, M. J., Hochhaus, A., Lang, F., Heinrich, M. C., Breccia, M., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 56

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Mauro, M. J., Hughes, T. P., Kim, D.-W., Rea, D., Cortes, J. E., Hochhaus, A., Sasaki, K., Breccia, M., Talpaz, M., Ottmann, O., et al. (2023) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 53

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Hochhaus, A., Burchert, A., Saussele, S., Baerlocher, G. M., Mayer, J., Brümmendorf, T. H., La Rosée, P., Heim, D., Krause, S. W., le Coutre, P., et al. (2023) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 21

Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results

Cortes, J. E., Lang, F., Rea, D., Hochhaus, A., Breccia, M., Goh, Y. T., Heinrich, M. C., Hughes, T. P., Janssen, J. J. W. M., le Coutre, P., et al. (2025) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 16

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results

Hochhaus, A., Kim, D.-W., Cortes, J. E., Sasaki, K., Mauro, M. J., Hughes, T. P., Breccia, M., Talpaz, M., Minami, H., Goh, Y. T., et al. (2025) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 14

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Cortes, J. E., Hochhaus, A., Hughes, T. P., Wang, J., Kim, D.-W., Kim, D. D. H., Mayer, J., Goh, Y. T., le Coutre, P., Etienne, G., et al. (2024) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 7

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Kohlbrenner, K., Galuschek, N., Fabarius, A., Reiser, M., Fenchel, K., Esseling, E., Göhler, T., Kühn, R.-B., Depenbusch, R., Talah Azeh, I., et al. (2023) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1